A Preliminary Study to Evaluate the Immune Response to a Booster Dose of the Adult Tetanus-Diphtheria Vaccine (Td) Available in Iran
| Author | Sepideh Noorian | en |
| Author | Negar Mottaghi-Dastjerdi | en |
| Author | Mohammad Soltany-Rezaee-Rad | en |
| Author | Hamed Montazeri | en |
| Author | Masoumeh Baghaei | en |
| Author | Mohammad-Javad Niazi | en |
| Orcid | Sepideh Noorian [0009-0001-2831-2626] | en |
| Orcid | Negar Mottaghi-Dastjerdi [0000-0001-8386-774X] | en |
| Orcid | Mohammad Soltany-Rezaee-Rad [0000-0002-0663-1140] | en |
| Orcid | Mohammad-Javad Niazi [0009-0004-7746-6295] | en |
| Issued Date | 2024-12-31 | en |
| Abstract | Background: Despite the availability of tetanus-diphtheria (TD) vaccines in Iran, the seroconversion rate of these products as a booster dose is unknown. Objectives: This study evaluates the seroconversion rate of the Iranian Td vaccine in adults who have not been vaccinated in the past decade. Methods: In this study, 20 adult volunteers aged 18 to 60 who had not received the Td vaccine in the past decade received a booster dose of the Iranian Td vaccine. Twenty-eight days after vaccination, the seroconversion rate was evaluated using the ELISA method. Vaccine adverse events were monitored at three time points after vaccination. Results: Seroconversion rates with the Iranian Td vaccine boosters were 75% and 90%, respectively, based on a 4-fold increase in anti-tetanus toxoid antibody titers and a 2- and 4-fold combination. Significant associations were found between the demographic data, specifically female gender and age 43 years and older, with seroconversion rates. Injection-site pain was the most common adverse reaction, with a frequency of 35%. No adverse events were reported between one week and one month after vaccination. Conclusions: Results showed that a booster dose of the Iranian Td vaccine produced a protective titer (> 0.1 IU/mL) and a long-term protective titer (> 1.0 IU/mL) in 100% of participants. The seroconversion rate of the Iranian Td vaccine was comparable to other common tetanus vaccines, including Tenivac®, Adacel®, Infanrix®, Tetavax®, and Vacteta®. The proportion of suitable candidates for plasma donation, based on minimum (2 IU/mL) and maximum (10 IU/mL) anti-tetanus toxoid antibody titers, was 100% and 45%, respectively. | en |
| DOI | https://doi.org/10.5812/ijpr-146572 | en |
| Keyword | Tetanus | en |
| Keyword | Tetanus Vaccine | en |
| Keyword | Seroconversion | en |
| Keyword | Booster Dose | en |
| Keyword | Hyper-Immune | en |
| Keyword | ELISA | en |
| Publisher | Brieflands | en |
| Title | A Preliminary Study to Evaluate the Immune Response to a Booster Dose of the Adult Tetanus-Diphtheria Vaccine (Td) Available in Iran | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijpr-23-1-146572-publish-pdf.pdf
- Size:
- 623.35 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF